Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer’s Disease
Author
dc.contributor.author
González, Andrea
Author
dc.contributor.author
Guzmán Martínez, Leonardo
Author
dc.contributor.author
Maccioni Baraona, Ricardo
Admission date
dc.date.accessioned
2021-03-25T15:47:39Z
Available date
dc.date.available
2021-03-25T15:47:39Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
J Alzheimers Dis . 2020;77(2):877-883
es_ES
Identifier
dc.identifier.other
10.3233/JAD-200386
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178796
Abstract
dc.description.abstract
Background: A major drawback in Alzheimer's disease (AD) is the lack of validated biomarkers for routine clinical diagnostic. We have reported earlier a novel blood biomarker, named Alz-tau (R), based on variants of platelet tau. This marker evaluates the ratio of high molecular weight tau (HMWtau) and the low molecular weight (LMWtau) tau.
Objective: To analyze a potential novel source of antigen for Alz-tau (R), plasma tau, detected by immunoreactivity with the novel monoclonal antibody, tau51.
Methods: We evaluated tau variants in plasma precipitated with ammonium sulfate from 36 AD patients and 15 control subjects by western blot with this novel monoclonal antibody.
Results: The HMW/LMWtau ratio was statistically different between AD patients and controls.
Conclusions: Plasma tau variants are suitable to be considered as a novel antigen source for the Alz-tau (R) biomarker for AD.
es_ES
Patrocinador
dc.description.sponsorship
Comisión Nacional de Investigación Científica y Tecnológica (CONICYT)
CONICYT FONDEF
Corfo-Innova grant
12IDL2-18218
Ricardo Benjamin Maccioni Foundation